Tests LY4086940 for weight management in adults with obesity or overweight
Tests LY4086940 against placebo in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
Key facts
- Where
- Buenos Aires and Rosario, ArgentinaSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07890376, who can take part
Where in Argentina
- CARDIAMET Investigaciones MédicasBuenos Aires, ArgentinaNo longer taking part
- Centro de Investigaciones Metabólicas (CINME)Buenos Aires, ArgentinaNo longer taking part
- Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaNo longer taking part
- Centro Médico ViamonteBuenos Aires, ArgentinaNo longer taking part
- Cicemo SrlBuenos Aires, ArgentinaNo longer taking part
- Mautalen Salud e InvestigaciónBuenos Aires, ArgentinaNo longer taking part
- Instituto Médico Catamarca IMECRosario, ArgentinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07890376
- Record updated
- 3 November 2026
- Original description
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.Read full original descriptionShow less
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.
Participation in the study will last about 58 weeks.
Inclusion: Meet inclusion criteria under Master Protocol CWMM (NCT06143956).
Exclusion: Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes; Have any of the following cardiovascular conditions within 6 months prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); unstable angina, or; hospitalization due to congestive heart failure; Within 6 months prior to screening, have taken medications (prescribed or over the counter) or alternative remedies (including herbal or nutritional supplements) that promote weight loss; Have a laboratory value suggestive of diabetes; In addition to exclusion criteria under Master Protocol CWMM (NCT06143956); Have a known personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma.